Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of “Buy” from Brokerages

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have earned a consensus recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $23.80.

Separately, Royal Bank of Canada restated an “outperform” rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday, January 21st.

Lexeo Therapeutics Price Performance

LXEO opened at $3.07 on Friday. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $101.51 million, a price-to-earnings ratio of -0.97 and a beta of 3.85. The business’s fifty day simple moving average is $4.59 and its 200-day simple moving average is $7.12. Lexeo Therapeutics has a 12-month low of $2.32 and a 12-month high of $19.50.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LXEO. Allostery Investments LP purchased a new position in shares of Lexeo Therapeutics during the 4th quarter worth approximately $33,000. BNP Paribas Financial Markets boosted its position in shares of Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of Lexeo Therapeutics during the fourth quarter worth $46,000. JPMorgan Chase & Co. lifted its stake in Lexeo Therapeutics by 135.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock worth $93,000 after acquiring an additional 5,915 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD acquired a new position in Lexeo Therapeutics in the 4th quarter valued at about $69,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.